SIU 2017: Transperineal Template-Guided Mapping Biopsy and Multiparametric MRI for Detection of Clinically Significant Prostate Cancer in Patients after initial Negative Trans-rectal Ultrasound-Guided Biopsy
Lisbon, Portugal (UroToday.com) Rising PSA after initial negative prostate biopsy is a dilemma in daily urological practice. In the past years multiparametric MRI (mpMRI) has been used to stratify patient risk of having clinically significant prostate cancer (PCa) and is helpful in preventing unnecessary prostate biopsy. The aim of this study was to evaluate the significance of mpMRI on detecting prostate cancer on repeat biopsy when transperineal prostate mapping (TPM) technique is applied.
SIU 2017: Combined Clinical Parameters and Multiparametric MRI for Advanced Risk Modeling of Prostate Cancer - Patient-Tailored Risk Stratification Can Reduce Unnecessary Biopsies
Lisbon, Portugal (UroToday.com) Multiparametric MRI (mpMRI) is gaining widespread acceptance in prostate cancer (PC) diagnosis and improves significant PC (Gleason score >3+4) detection. Decision-making based on European Randomized study of Screening for PC (ERSPC) risk-calculator (RC) parameters may overcome PSA-limitations. The authors added pre-biopsy mpMRI to ERSPC-RC parameters and developed risk models (RM) to predict individual significant PC-risk for biopsy-naive men and men after a previous biopsy.
SIU 2017: Correlation of mpMRI Contours with 3-Dimensional 5mm Transperineal Prostate Mapping Biopsy within the PROMIS Trial Pilot: What Margins Are Required?
Lisbon, Portugal (UroToday.com) It is known that mpMRI offers the possibility to locate cancer in a three dimensional space and aid surgical planning. In this study the authors investigated the margin needed around an mpMRI lesion for complete disease control in a prospectively enrolled biopsy naive population, who underwent mpMRI followed by Transperineal Prostate Mapping with biopsies taken every 5mm (5TPM).
SIU 2017: Outcomes of Cognitive MRI Targeted TRUS Biopsy of Prostate
Lisbon, Portugal (UroToday.com) Trans-rectal ultrasound guided biopsy of prostate (TRUS-BP) is the gold standard diagnostic investigation for patients presenting with an abnormal PSA and/or abnormal digital rectal examination. However, this procedure entails significant risks.
SIU 2017: Correlation between Multiparametric MRI PIRADS Scores and Prostate Carcinoma Grade Grouping on Transperineal Template +/- Targeted Biopsy
Lisbon, Portugal (UroToday.com) In this study the authors correlated 3T multiparametric MRI PIRADS results with transperineal template biopsy grade group scores. This data was also used to produce sensitivity and specificity results of 3T multiparametric MRI for the detection of clinically significant prostate cancer (Grade Group 2 or greater).
SIU 2017: Prostate Cancer Can Be Detected Even in Patients with Decreased PSA after Antibiotic Therapy
Lisbon, Portugal (UroToday.com) Aside from prostate cancer, prostatitis can cause an elevation of Prostate Specific Antigen (PSA). The authors attempted to evaluate whether a biopsy was needed after decrease of PSA upon administration of antibiotics. The authors compared the biopsy positive rate of the patients with decreased PSA after antibiotics administration, and patients who underwent the biopsy with a high PSA without the administration of antibiotics.
SIU 2017: Automatic Grading of Prostate Cancer using the Gleason Grading Groups
Lisbon, Portugal (UroToday.com) Prostate cancer (PCa) grade in the diagnostic biopsy is an important determinant of patient management. The Gleason grading groups (GGG) are recently introduced for grading of prostate cancer. This new scoring system is subject to a similar inter-observer agreement as the Gleason score (60%). Computer aided diagnosis systems using convolutional neural networks (CNN) have shown to approach human performance in diagnosing skin disease, while reducing inter-observer variability.